COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Treatment Based on Molecular Profiling Diagnosis Carcinoma of Unknown Primary Site

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00737243
Recruitment Status : Completed
First Posted : August 18, 2008
Results First Posted : August 17, 2016
Last Update Posted : August 17, 2016
Genentech, Inc.
Information provided by (Responsible Party):
SCRI Development Innovations, LLC

Brief Summary:
This is a non-randomized Phase II study. Patients determined at initial diagnosis to have a carcinoma of unknown primary site (CUP) will have their treatment selected with the use of a molecular profiling assay. The assay will be performed on paraffin-embedded tumor tissue from a biopsy specimen. Patients given specific diagnoses (e.g., lung, pancreas, colon, breast, renal cell, prostate and ovarian cancer) will receive treatment regimens of proven activity. If no specific diagnosis is made with the molecular profiling assay, empiric chemotherapy with paclitaxel, carboplatin, bevacizumab and erlotinib will be administered.

Condition or disease Intervention/treatment Phase
Carcinoma Drug: Paclitaxel Drug: Carboplatin Drug: Bevacizumab Drug: Erlotinib Other: Treatment determined by physician Phase 2

Detailed Description:
The primary objective of the study is evaluate the impact of the molecular assay prediction on the efficacy of therapy for patients with carcinoma of unknown primary site (CUP). Investigators will use tumor profiling results to direct standard, site-specific first-line therapy for patients with CUP.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 289 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Phase II Study of Chemotherapy Treatment Based on Molecular Profiling Diagnosis for Patients With Carcinoma of Unknown Primary Site
Study Start Date : August 2008
Actual Primary Completion Date : November 2012
Actual Study Completion Date : December 2012

Resource links provided by the National Library of Medicine

Arm Intervention/treatment
Experimental: Paclitaxel, Carboplatin, Bevacizumab and Erlotinib
Paclitaxel, Carboplatin, Bevacizumab and Erlotinib
Drug: Paclitaxel
175 mg/m2, 1-3 hour IV infusion Day 1

Drug: Carboplatin
AUC 6.0 IV Day 1

Drug: Bevacizumab
15 mg/kg IV infusion Day 1
Other Name: Avastin

Drug: Erlotinib
150 mg PO
Other Name: Tarceva

Treatment determined by physician
Other treatment determined by physician based on molecular profiling assay
Drug: Bevacizumab
15 mg/kg IV infusion Day 1
Other Name: Avastin

Drug: Erlotinib
150 mg PO
Other Name: Tarceva

Other: Treatment determined by physician
Patients Assigned a Specific Diagnosis by the Molecular profiling Assay will have physician's choice therapy

Primary Outcome Measures :
  1. Overall Survival [ Time Frame: every 6-8 weeks (2 cycles) until death from any cause or lost to follow up, projected 18 months ]
    Defined as the elapsed time from the start of treatment to the date of death from any cause or lost to follow-up. Participants lost to follow up were censored as of the last date known to be alive.

Secondary Outcome Measures :
  1. Number of Participants With a Tissue of Origin Successfully Predicted by the Assay [ Time Frame: at baseline ]
    To evaluate the utility of the assay in identifying the tissue of origin in patients with carcinoma of unknown primary site (CUP), an archived tumor specimen was assayed upon study entry. If a tissue of origin was predicted by the assay, participants received standard site-specific therapy for that tumor type. When tissue of origin was not predicted by the assay, patients received standard empiric chemotherapy for CUP and were not followed further. If the assay was not completed due to inadequate amount of tumor in the biopsy specimen, patients were not treated on the study.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  1. Patients must have carcinoma of unknown primary site after the following diagnostic procedures have been performed and are unrevealing of a primary site:

    • Complete medical history and physical examination,
    • Complete blood counts, chemistry profile,
    • CT scans of the chest and abdomen,
    • Directed evaluation of any symptomatic areas,
    • PET scan (recommended).
  2. Patients must have biopsy-proven metastatic carcinoma, with any of the following light microscopic histologies:

    • Adenocarcinoma,
    • Poorly differentiated adenocarcinoma,
    • Poorly differentiated carcinoma (all patients with poorly differentiated carcinoma must have immunoperoxidase stains to rule out other treatable malignancies [e.g., lymphoma, neuroendocrine carcinoma]),
    • Poorly differentiated squamous carcinoma.
  3. Patients must have biopsy material available from a surgical biopsy, a core needle biopsy, or a fine needle aspiration biopsy to provide an adequate specimen (must be 40% tumor) for the molecular profiling assay.
  4. An ECOG performance status 0, 1, or 2.
  5. No previous treatment with any systemic therapy.
  6. Measurable or evaluable disease according to the Response Evaluation Criteria in Solid Tumors (RECIST).
  7. Laboratory values as follows:

    • WBC 4000/micro L,
    • Platelets 100,000/micro L,
    • Serum bilirubin <1.5 times the institutional upper limits of normal (ULN),
    • Serum creatinine < 2.0 mg/dL.
  8. Patients with brain metastases are eligible only if all lesions have been controlled by surgical resection or radiation therapy, the patient is not steroid-dependent, and the patient meets all other eligibility criteria.
  9. Patients must be > 4 weeks from any major operative procedure.
  10. To be eligible for the TREATMENT portion of the study, patients must have one of the five following diagnoses: colorectal, pancreas, NSCLC, ovary, renal cancer.
  11. Patients must be able to understand the nature of this study and give written informed consent.

Exclusion Criteria:

  1. Patients with the following specific syndromes are not eligible:

    • Patients with neuroendocrine carcinoma,
    • Women with adenocarcinoma isolated to axillary lymph nodes,
    • Women with adenocarcinoma isolated to peritoneal involvement,
    • Patients with carcinoma involving only 1 site, with resectable tumor at that site, or
    • Patients with squamous carcinoma limited to cervical, supraclavicular, or inguinal lymph nodes.
  2. Patients with uncontrolled brain metastases and all patients with meningeal metastases.
  3. Patients with insufficient biopsy material available for molecular profiling assay.
  4. Women who are pregnant or lactating. All females of child-bearing potential must have a negative serum or urine pregnancy tests within 7 days prior to study treatment.
  5. Men and women of childbearing potential are required to use effective methods of contraception during this study and for 6 months after ending therapy.
  6. Patients who have received any other experimental drug within 28 days of starting treatment.

Exclusion Criteria for All Patients Receiving Bevacizumab-Containing Regimens

  1. Patients with history of acute myocardial infarction within 6 months, other clinically significant cardiovascular disease (e.g., unstable angina, New York Heart Association [NYHA] grade 2 congestive heart failure [CHF], serious cardiac arrhythmias requiring medication) or > grade 2 vascular disease.
  2. Patients with uncontrolled hypertension (systolic blood pressure [BP] 150 or diastolic BP >100mm Hg) or uncontrolled cardiac arrhythmias.
  3. Prior hypertensive crisis or hypertensive encephalopathy.
  4. Patients with clinical history of hemoptysis (defined as bright red blood of

    ½ teaspoon per episode) or hematemesis within 1 month prior to Day 1.

  5. Patients with PEG tubes or G tubes.
  6. Major surgical procedure, open biopsy, or significant traumatic injury within 28 days prior to Day 1 or anticipation of need for major surgical procedure during the course of the study.
  7. Core biopsy or other minor surgical procedure excluding placement of a vascular access device, within 7 days prior to Day 1.
  8. Significant vascular disease (e.g., aortic aneurysm requiring surgical repair or recent peripheral arterial thrombosis) within 6 months prior to Day 1.
  9. Patients with proteinuria (1000 mg/24 hours) at screening will be excluded. A 24-hour urine collection is not required in all patients (e.g., patients whose treatment plans exclude bevacizumab); however, all patients receiving bevacizumab with 1+ proteinuria on dipstick urinalysis at study entry must have a subsequent 24-hour urine collection.
  10. Patients with any non-healing wound, ulcer, or long bone fracture.
  11. Patients with any history of a bleeding diathesis or coagulopathy (in the absence of therapeutic anticoagulation).
  12. Patients with a history of abdominal fistula, gastrointestinal perforation, or intra-abdominal abscess within 6 months prior to beginning bevacizumab.
  13. Patients with a history of stroke or transient ischemic attach within 6 months prior to first bevacizumab dose.
  14. Known hypersensitivity to any component of bevacizumab.
  15. Patients with history of any other disease, physical examination finding, or clinical laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of a novel regimen, or that might affect the results of this study or render the subject at high risk for treatment complications.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00737243

Show Show 21 study locations
Sponsors and Collaborators
SCRI Development Innovations, LLC
Genentech, Inc.
Layout table for investigator information
Study Chair: John D Hainsworth, M.D. SCRI Development Innovations, LLC
Publications automatically indexed to this study by Identifier (NCT Number):
Layout table for additonal information
Responsible Party: SCRI Development Innovations, LLC Identifier: NCT00737243    
Other Study ID Numbers: SCRI UNKPRI 20
First Posted: August 18, 2008    Key Record Dates
Results First Posted: August 17, 2016
Last Update Posted: August 17, 2016
Last Verified: July 2016
Keywords provided by SCRI Development Innovations, LLC:
Carcinoma of Unknown Primary Site
Molecular profiling assay
Additional relevant MeSH terms:
Layout table for MeSH terms
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Erlotinib Hydrochloride
Antineoplastic Agents, Phytogenic
Antineoplastic Agents
Tubulin Modulators
Antimitotic Agents
Mitosis Modulators
Molecular Mechanisms of Pharmacological Action
Antineoplastic Agents, Immunological
Angiogenesis Inhibitors
Angiogenesis Modulating Agents
Growth Substances
Physiological Effects of Drugs
Growth Inhibitors
Protein Kinase Inhibitors
Enzyme Inhibitors